Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.

[1]  S. Pocock,et al.  Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention , 2020, Circulation. Cardiovascular interventions.

[2]  M. Postma,et al.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.

[3]  W. Rottbauer,et al.  Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.

[4]  H. Suryapranata,et al.  Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials. , 2019, Atherosclerosis.

[5]  H. Suryapranata,et al.  Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients , 2018, Pharmacological research.

[6]  H. Suryapranata,et al.  Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  N. Tang,et al.  Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: comment , 2016, Journal of thrombosis and haemostasis : JTH.

[8]  H. Suryapranata,et al.  Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy , 2016, Cardiovascular Drugs and Therapy.

[9]  H. Suryapranata,et al.  Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. , 2016, Vascular pharmacology.

[10]  H. Suryapranata,et al.  Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor , 2016, Journal of thrombosis and haemostasis : JTH.

[11]  I. Amiri,et al.  The Role of G22 A Adenosine Deaminase 1 Gene Polymorphism and the Activities of ADA Isoenzymes in Fertile and Infertile Men. , 2015, Urology.

[12]  D. Voora,et al.  Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. , 2015, European heart journal.

[13]  H. Suryapranata,et al.  Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. , 2014, JACC. Cardiovascular interventions.

[14]  G. De Luca,et al.  Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management: A Meta-analysis of Randomized Trials , 2014, Journal of cardiovascular pharmacology.

[15]  J. Sidaway,et al.  Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.

[16]  Wu Wei,et al.  Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. , 2013, Archives of cardiovascular diseases.

[17]  G. Stone,et al.  Time course, predictors and clinical implications of stent thrombosis following primary angioplasty , 2013, Thrombosis and Haemostasis.

[18]  G. Stone,et al.  Impact of age on long-term outcome after primary angioplasty with bare-metal or drug-eluting stent (from the DESERT cooperation). , 2013, The American journal of cardiology.

[19]  H. Suryapranata,et al.  A meta-analytic overview of thrombectomy during primary angioplasty. , 2013, International journal of cardiology.

[20]  H. Suryapranata,et al.  PlA1/PlA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  G. Stone,et al.  Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. , 2013, The American journal of cardiology.

[22]  M. Vidali,et al.  Role of the laboratory in monitoring patients receiving dual antiplatelet therapy , 2012, International journal of laboratory hematology.

[23]  H. Suryapranata,et al.  Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. , 2012, Atherosclerosis.

[24]  J. Sidaway,et al.  Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model , 2012, Journal of cardiovascular pharmacology and therapeutics.

[25]  K. Nelander,et al.  Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism , 2012, Journal of thrombosis and haemostasis : JTH.

[26]  G. De Luca,et al.  Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[27]  G. Stone,et al.  Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. , 2012, Archives of internal medicine.

[28]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[29]  D. Dudek,et al.  Early glycoprotein IIb‐IIIa inhibitors in primary angioplasty‐abciximab long‐term results (EGYPT‐ALT) cooperation: individual patient’s data meta‐analysis , 2011, Journal of thrombosis and haemostasis : JTH.

[30]  S. de Servi,et al.  Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[31]  A. Oliani,et al.  The ADA*2 allele of the adenosine deaminase gene (20q13.11) and recurrent spontaneous abortions: an age-dependent association , 2011, Clinics.

[32]  S. de Servi,et al.  Low‐molecular‐weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST‐elevation myocardial infarction: a meta‐analysis , 2011, Journal of thrombosis and haemostasis : JTH.

[33]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[34]  M. Bogo,et al.  Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients. , 2010, Revista brasileira de psiquiatria.

[35]  V. Napolioni,et al.  Gender-specific association of ADA genetic polymorphism with human longevity , 2010, Biogerontology.

[36]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[37]  F. Giordanetto,et al.  Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation , 2009, Journal of thrombosis and haemostasis : JTH.

[38]  A. Gori,et al.  Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. , 2009, American journal of clinical pathology.

[39]  B. Giusti,et al.  Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. , 2009, The American journal of cardiology.

[40]  B. Franke,et al.  The 22G>A polymorphism in the adenosine deaminase gene impairs catalytic function but does not affect reactive hyperaemia in humans in vivo , 2008, Pharmacogenetics and genomics.

[41]  A. Kastrati,et al.  Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. , 2008, European heart journal.

[42]  N. Bottini,et al.  Adenosine Deaminase Genetic Polymorphism and Coronary Artery Disease , 2008, Cardiology.

[43]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[44]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[45]  W. Oyen,et al.  Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. , 2007, European heart journal.

[46]  K. Safranow,et al.  ADA*2 Allele of the Adenosine Deaminase Gene May Protect against Coronary Artery Disease , 2007, Cardiology.

[47]  C. Indolfi,et al.  Direct coronary stenting: Effect on coronary blood flow, immediate and late clinical results , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[48]  W. Schrader,et al.  Localization of adenosine deaminase and adenosine deaminase complexing protein in rabbit heart. Implications for adenosine metabolism. , 1990, Circulation research.

[49]  R. Scozzari,et al.  Comparative activity of red cell adenosine deaminase allelic forms , 1974, Nature.

[50]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[51]  B. Jilma,et al.  The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. , 2015, Clinical science.

[52]  Volkmar Falk,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca , 2014, European heart journal.